Biotech Values

[DewDiligence]

FDA advisory panel votes 14-1 against SNY’s Semuloparin anticoagulant as a prophylactic for chemotherapy patients:

http://online.wsj.com/article/SB10001424052702304898704577478600549029584.html

Hard to believe that SNY once touted this drug as the replacement for Lovenox; see #msg-76717361 for background.